Bristol-Myers Squibb stock trades steady as Opdivo and Eliquis underpin revenue and margins

Bristol-Myers Squibb stock represents one of the larger US pharma positions in the S&P 500, with the New York based company (ISIN US1078421011) relying heavily on key brands such as cancer drug Opdivo and blood thinner Eliquis for revenue and profit. The latest widely reported quarterly figures for Bristol-Myers Squibb showed global revenue of around $11.3 billion for a recent quarter in 2023, up roughly 3% from the same period a year earlier, according to company disclosures and financial portal summaries as of 2023, highlighting how incremental growth is being maintained despite mounting patent challenges. For investors, the mix between legacy blockbusters and newer launches now sits at the center of how Bristol-Myers Squibb stock is judged over the medium term.

Revenue near $11 billion with shifting mix

According to widely cited Bristol-Myers Squibb quarterly results for 2023, total revenue for one of the main reported quarters was approximately $11.3 billion, compared with about $10.9 billion in the prior year quarter, implying year on year growth of around 3.7%. This modest rise came even as some mature brands began to feel generic pressure, illustrating that the portfolio of oncology, immunology, and cardiovascular drugs still delivered incremental top line expansion. In that same reporting period, Bristol-Myers Squibb management emphasized that foreign exchange effects and pricing dynamics were relatively manageable, allowing underlying volume trends to remain the primary driver of the revenue increase.

Within that roughly $11.3 billion quarterly total, branded therapies such as Opdivo and Eliquis contributed a large share. Publicly reported segment information for 2023 showed that Eliquis, which Bristol-Myers Squibb co markets with a partner, generated quarterly revenue of around $3 billion, up from about $2.8 billion in the comparable 2022 quarter, a rise of roughly 7% year on year. This lift partly offset pressure in other parts of the cardiovascular portfolio. Opdivo, Bristol-Myers Squibb's immuno oncology therapy, added a further approximate $2 billion to $2.3 billion in quarterly sales depending on the specific 2023 quarter cited, with high single digit to low double digit percentage growth versus the prior year as new indications and international uptake continued.

The revenue mix clarified a central tension for Bristol-Myers Squibb stock. On the one hand, Eliquis and Opdivo together accounted for more than 40% of quarterly revenue in some 2023 periods, underlining how concentrated the business has become around a handful of blockbuster brands. On the other hand, the company also reported 2023 revenue in newer categories such as cell therapies and immunology drugs, which collectively generated more than $1 billion in quarterly sales and grew more than 20% year on year from a lower base. For investors, the quantified comparison between modest overall revenue growth of roughly 3% and much faster growth in the newer portfolio suggests that future performance will increasingly depend on how quickly these emerging franchises scale to balance eventual patent expiries.

Operating profit and margin trends around 25 percent

Profitability metrics from Bristol-Myers Squibb's 2023 reporting showed that operating income remained substantial, even as investment in research and development stayed high. In a representative 2023 quarter, Bristol-Myers Squibb reported operating income of roughly $2.8 billion on revenue of about $11.3 billion, implying an operating margin near 25%. That compared with operating income closer to $3.0 billion and margin roughly 27% in the prior year quarter when revenue was about $10.9 billion, indicating a modest margin compression of around 2 percentage points year on year. The decline reflected higher amortization from past acquisitions and an increase in R&D spending aimed at sustaining the pipeline beyond current blockbusters.

Net income for that same period was reported in the range of $2.0 billion to $2.3 billion, equating to diluted earnings per share of approximately $1.00 to $1.15 depending on the quarter and share count adjustments. This earnings level compared with a prior year quarterly EPS closer to $1.45, meaning that EPS decreased by roughly 20% to 30% year on year, even though revenue still grew. For Bristol-Myers Squibb stock holders, that difference between revenue growth and EPS decline highlighted how non operating factors such as one time charges, acquisition related expenses, and share repurchases can significantly sway the bottom line, making margins and cash flow just as important as reported net income in assessing performance.

Cash generation figures gave additional context. For full year 2023, Bristol-Myers Squibb reported operating cash flow in the vicinity of $17 billion, while free cash flow after capital expenditures stood around $13 billion to $14 billion. Compared with 2022, when operating cash flow was somewhat higher, near $18 billion, this represented a small decline as working capital needs and higher capital investments increased. However, the company still maintained a free cash flow margin above 30% of revenue for the year, enabling ongoing dividend payments and debt reduction while reserving room for selective bolt on acquisitions.

Eliquis and Opdivo anchor billions in annual sales

Drilling into product level metrics shows how central Eliquis and Opdivo are to Bristol-Myers Squibb stock. For the full year 2023, widely reported data for Bristol-Myers Squibb indicated that Eliquis worldwide revenue was roughly $11 billion, compared with nearly $10 billion in 2022, an increase of around $1 billion or about 10% year on year. This growth came from wider adoption in stroke prevention and treatment of atrial fibrillation, particularly outside the US, even as pricing and reimbursement constraints in some markets moderated the pace. The fact that a single cardiovascular drug contributes nearly one third of total company sales underlines both the strength and the concentration risk in Bristol-Myers Squibb's portfolio.

Opdivo followed a similar but more diversified trajectory. For 2023, Opdivo annual revenue was reported around $8 billion, up from roughly $7 billion in 2022, a rise of about 14%. Growth was driven by expanded indications in lung, renal, and gastrointestinal cancers, along with combination regimens that improved overall survival in certain tumor types. From an investor standpoint, this double digit growth in a major oncology brand helped maintain Bristol-Myers Squibb's positioning in immuno oncology despite intensifying competition from other PD 1 and PD L1 inhibitors. It also provided evidence that the company is still capable of driving innovation based growth within its existing portfolio.

Newer assets such as cell therapy products Abecma and Breyanzi, as well as immunology treatment Sotyktu, added incremental growth. Combined, these newer launches generated more than $1.5 billion in 2023 revenue, according to public company figures, versus around $1.0 billion in 2022, representing growth of more than 50% year on year from a lower base. While these amounts remain small relative to Eliquis and Opdivo, the steep growth trajectory is important for Bristol-Myers Squibb stock because it signals a potential path to offsetting future revenue losses once patent exclusivity for Eliquis begins to phase out in major markets later this decade.

Pipeline and patent expiry dynamics

Bristol-Myers Squibb has consistently guided the market to expect a transition period as major brands face patent challenges. Company presentations across 2023 and 2024 outlined that drugs such as Eliquis will likely see generic competition beginning in the second half of the decade, with potential revenue erosion of several billion dollars per year over time if not countered by new launches. Management has therefore prioritized late stage pipeline candidates and recently launched therapies with peak sales prospects in the billions. For example, Sotyktu, a once daily TYK2 inhibitor for psoriasis, has been described in company messaging as having multi billion dollar peak sales potential, while cell therapies aim at niche but high value indications.

Analyst consensus information for 2025 and 2026, as aggregated by financial data providers, generally projects that Bristol-Myers Squibb's total revenue could remain in the mid $40 billion range annually, with low single digit percentage growth overall. However, the composition of that revenue is expected to shift, with Eliquis and Opdivo contributing somewhat less as a share of the total while the new product portfolio rises from around 10% of revenue currently to 25% or more by the late 2020s. This quantified consensus shift underscores how important the success or failure of the pipeline is to the valuation of Bristol-Myers Squibb stock.

In the meantime, Bristol-Myers Squibb has focused on cost discipline and capital allocation. Reported 2023 figures show research and development expenses near $9 billion for the year, equivalent to about 20% of revenue, compared with roughly $8.2 billion and 18% of revenue in 2022. The increase in R&D intensity illustrates the extent to which management is willing to invest to sustain the drug pipeline. At the same time, selling, general, and administrative expenses have been held relatively stable, helping keep overall operating margins in the mid 20% range despite the rising R&D burden.

Opdivo and Eliquis shape the product story

Opdivo, Bristol-Myers Squibb's flagship immuno oncology therapy, is indicated in multiple tumor types, including melanoma, non small cell lung cancer, renal cell carcinoma, and several gastrointestinal cancers. Full year 2023 figures of roughly $8 billion in Opdivo sales compared with around $7 billion in 2022 show that the product can still grow mid teens percentages despite competition from other checkpoint inhibitors. This growth reflects both expanded labels in major markets and deeper penetration into earlier lines of treatment where clinical data have demonstrated survival benefits. For Bristol-Myers Squibb stock, the resilience of Opdivo revenue helps reassure investors that oncology remains a strong pillar of the business.

Eliquis, the oral anticoagulant co developed with a partner, continues to be one of the most prescribed blood thinners globally. Its approximately $11 billion in revenue for 2023, up from nearly $10 billion in 2022, evidences high single digit to low double digit percentage growth even as some markets face pricing scrutiny. The therapy's role in reducing stroke risk in atrial fibrillation and its relatively favorable bleeding profile compared with older anticoagulants supports sustained demand. At the same time, upcoming patent expirations in key geographies during the second half of the decade mean that investors closely watch legal developments and generic filings related to Eliquis, because a multi billion dollar revenue stream is at stake.

Bristol-Myers Squibb has also begun to highlight newer products as future growth drivers. Cell therapy assets such as Abecma and Breyanzi treat specific hematologic malignancies with personalized approaches; their combined 2023 revenue above $1 billion compared with about $0.6 billion in 2022 shows more than 60% year on year growth. This steep increase demonstrates early commercial traction, even though manufacturing complexity and regulatory oversight remain demanding. Oral immunology drug Sotyktu for psoriasis, introduced more recently, has started to scale from a low base, with management signaling multi billion dollar potential over time if uptake in dermatology continues as expected.

Bristol-Myers Squibb stock price and valuation context

On major US exchanges, Bristol-Myers Squibb is primarily listed on the New York Stock Exchange under the ticker symbol BMY. Market data from recent 2024 and 2025 trading sessions show that Bristol-Myers Squibb stock has commonly traded in a range around the mid $40s to low $50s per share, with a 52 week range roughly spanning from the high $30s to the mid $50s. That put the market capitalization of Bristol-Myers Squibb near $90 billion to $100 billion during those periods, assuming a basic share count of around 2 billion. These values position the company among the larger global pharmaceutical groups, though smaller than the very largest giants in the sector.

Dividend metrics add another layer for investors. Bristol-Myers Squibb's declared annual dividend in 2023 amounted to roughly $2.28 per share, up from about $2.16 per share in 2022, equating to an increase of around 5.6% year on year. At a share price of $50, that would correspond to a dividend yield of about 4.6%, which is relatively high within the large cap pharma peer group. The combination of a sizeable dividend and solid free cash flow suggests that income oriented investors view Bristol-Myers Squibb stock as a potential yield component within diversified portfolios, though future cash flow will depend on how effectively the company navigates patent cliffs and competitive dynamics.

From a valuation perspective, consensus estimates in recent years have typically placed Bristol-Myers Squibb's forward price to earnings multiple in the high single digit to low double digit range, often around ten times forward earnings. This level is lower than some faster growing biotech peers, reflecting both the maturity of key brands and concerns over upcoming patent expiries. However, when measured against free cash flow, the valuation sometimes appears more favorable, with an implied free cash flow yield near 10% in certain 2023 and 2024 snapshots. For long term holders, the tension between near term patent headwinds and longer term pipeline prospects is embedded in these valuation ratios.